Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions

Ann Hematol. 2019 Aug;98(8):2019-2020. doi: 10.1007/s00277-019-03680-4. Epub 2019 Apr 2.

Authors

Marian Müller¹, Ricarda Graf², Karl Kashofer³, Susanne Macher⁴, Albert Wölfler¹, Armin Zebisch¹, Andelko Hrzenjak^{5

6}, Ellen Heitzer², Heinz Sill⁷

Affiliations

¹ Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, A-8036, Graz, Austria.
² Institute of Human Genetics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
³ Institute of Pathology, Medical University of Graz, Graz, Austria.
⁴ Department for Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
⁵ Division of Pulmonology, Medical University of Graz, Graz, Austria.
⁶ Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
⁷ Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, A-8036, Graz, Austria. heinz.sill@medunigraz.at.

No abstract available

Publication types

Letter

MeSH terms

Bone Marrow / pathology
Cell Differentiation / drug effects
Cell Hypoxia / genetics*
DNA, Neoplasm / genetics
Genes, Neoplasm*
Genes, p53*
Humans
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / pathology
Mesenchymal Stem Cells / chemistry*
Mesenchymal Stem Cells / drug effects
Mesenchymal Stem Cells / pathology
Mutation*
Neoplasm Proteins / genetics*
Neoplastic Stem Cells / chemistry*
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / pathology
Oxygen / pharmacology
Polymorphism, Single Nucleotide
Tumor Cells, Cultured
Tumor Microenvironment
Tumor Suppressor Protein p53 / genetics*

Substances

DNA, Neoplasm
Neoplasm Proteins
TP53 protein, human
Tumor Suppressor Protein p53
Oxygen

Grants and funding

P 31430/FWF_/Austrian Science Fund FWF/Austria